Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia

Novel therapies for AML: a round-up for clinicians

(2021) Mahesh Swaminathan et al.   Expert Review of Clinical Pharmacology

Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents

(2021) Tamer A. Othman et al.   AMERICAN JOURNAL OF HEMATOLOGY

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

(2020) Nicholas J. Short et al.   Cancer Discovery

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).

(2020) Tara L. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

(2020) Curtis Andrew Lachowiez et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

(2020) Chong Chyn Chua et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

(2020) Erika Morsia et al.   AMERICAN JOURNAL OF HEMATOLOGY

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

(2020) Nicholas J. Short et al.   JAMA Oncology

Targeting the Bcl-2 Family in B Cell Lymphoma

(2019) Clare M. Adams et al.   Frontiers in Oncology

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolutionary trajectory of leukemic clones and its clinical implications

(2019) Amos Tuval et al.   HAEMATOLOGICA

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

(2019) Brian Ball et al.   HAEMATOLOGICA

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

(2019) Nicholas J. Short et al.   HAEMATOLOGICA

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

(2019) Suresh Agarwal et al.   HEMATOLOGICAL ONCOLOGY

How I treat acute myeloid leukemia in the era of new drugs

(2019) Courtney D. DiNardo et al.   BLOOD

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

(2019) Yumeng Zhang et al.   BLOOD

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

(2019) Brian A. Jonas et al.   LEUKEMIA

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

New and emerging therapies for acute myeloid leukaemia

(2018) Julian R Davis et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

(2016) Hong Liu et al.   DRUG METABOLISM AND DISPOSITION

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Mitochondria—Judges and Executioners of Cell Death Sentences

(2016) Patrick D. Bhola et al.   MOLECULAR CELL

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

The graceful exit or reluctant demise of the older adult with acute myeloid leukemia

(2015) Mikkael A. Sekeres et al.   CANCER

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

How I treat the older patient with acute myeloid leukemia

(2014) G. Ossenkoppele et al.   BLOOD

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

(2014) C. S. Grove et al.   Disease Models & Mechanisms

Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis

(2013) Oliver Teuffel et al.   BRITISH JOURNAL OF HAEMATOLOGY

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

(2013) Roelof Willemze et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Current treatment of acute myeloid leukemia

(2012) Gail J. Roboz   CURRENT OPINION IN ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry

(2011) Gunnar Juliusson   Clinical Lymphoma Myeloma & Leukemia

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

(2011) Haifa K. Al-Ali et al.   LEUKEMIA & LYMPHOMA

Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia

(2010) Ellen K. Ritchie et al.   Current Hematologic Malignancy Reports

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE